{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:15Z","timestamp":1791357375645,"version":"4.3.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.mcna.2014.08.013","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T06:51:37Z","timestamp":1413615097000},"page":"107-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Incretin-Based Therapies"],"prefix":"10.1016","volume":"99","author":[{"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2014.08.013_bib1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2014.08.013_bib2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.mcna.2014.08.013_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01225454","article-title":"The incretin concept today","volume":"16","author":"Creutzfeldt","year":"1979","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5910","key":"10.1016\/j.mcna.2014.08.013_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mcna.2014.08.013_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.mcna.2014.08.013_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"issue":"8571","key":"10.1016\/j.mcna.2014.08.013_bib9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcna.2014.08.013_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"9548","key":"10.1016\/j.mcna.2014.08.013_bib11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2014.08.013_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1530\/eje.0.1430717","article-title":"Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function","volume":"143","author":"Perfetti","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.mcna.2014.08.013_bib13","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.mcna.2014.08.013_bib14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diab.45.6.832","article-title":"Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I","volume":"45","author":"Orskov","year":"1996","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0306-4522(96)00434-4","article-title":"Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem","volume":"77","author":"Larsen","year":"1997","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tcm.2010.02.012","article-title":"Glucagon-like peptide 1- a cardiologic dimension","volume":"20","author":"Treiman","year":"2010","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.mcna.2014.08.013_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.beem.2009.03.001","article-title":"Therapeutic potential for GIP receptor agonists and antagonists","volume":"23","author":"Irwin","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.mcna.2014.08.013_bib19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsboll","year":"2002","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.mcna.2014.08.013_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.mcna.2014.08.013_bib21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","article-title":"Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia","volume":"46","author":"Meier","year":"2003","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.mcna.2014.08.013_bib22","doi-asserted-by":"crossref","first-page":"e9590","DOI":"10.1371\/journal.pone.0009590","article-title":"A\u00a0GIP receptor agonist exhibits \u03b2-cell anti-apoptotic actions in rat models of diabetes resulting in improved \u03b2-cell function and glycemic control","volume":"5","author":"Widenmaier","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.42.5.658","article-title":"Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable","volume":"42","author":"Orskov","year":"1993","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clinthera.2011.04.015","article-title":"Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus","volume":"33","author":"Campbell","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.mcna.2014.08.013_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.mcna.2014.08.013_bib26","unstructured":"Byetta (exenatide) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib27","unstructured":"Victoza (liraglutide) [package insert]. Plainsboro, NJ: Novo Nordisk, Inc; 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib28","unstructured":"Bydureon (exenatide extended-release for injectable suspension) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib29","unstructured":"Tanzeum (albiglutide) [package insert]. Wilmington, DE: GlaxoSmithKline, LLC; 2014."},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.mcna.2014.08.013_bib31","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.mcna.2014.08.013_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2014.08.013_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.mcna.2014.08.013_bib36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes mellitus (LEAD-4 Met\u00a0+ TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib37","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met\u00a0+ SU): a randomized controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"9645","key":"10.1016\/j.mcna.2014.08.013_bib38","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2014.08.013_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION 1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"issue":"9739","key":"10.1016\/j.mcna.2014.08.013_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"issue":"9733","key":"10.1016\/j.mcna.2014.08.013_bib41","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib42","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide one weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mcna.2014.08.013_bib43","unstructured":"Reusch J, Stewart M, Perkins C, et\u00a0al. HARMONY 1 week 52 results: albiglutide vs. placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone \u00b1 metformin [abstract 57-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21\u201325, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib44","unstructured":"Nauck M, Stewart M, Perkins C, et\u00a0al. HARMONY 2 Wk 52 results: albiglutide monotherapy in drug na\u00efve patients with type 2 diabetes mellitus [abstract 55-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21\u201325, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib45","unstructured":"Reinhardt R, Nauck MA, Stewart M, et\u00a0al. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [abstract 903]. In: Programs and abstracts of the 49th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 23\u201327, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib46","unstructured":"Ahren B, Stewart M, Cirkel D, et\u00a0al. HARMONY 3: 104 week (wk) efficacy of albiglutide (Albi) compared to sitagliptin (Sita) and glimepiride (SU) in patients (pts) with type 2 diabetes mellitus (T2DM) on metformin (Met) [abstract 52-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21\u201325, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib47","unstructured":"Johnson S, Ahren B, Stewart M, et\u00a0al. HARMONY 3: 104 week efficacy of albiglutide compared to sitagliptin and glimepiride in patients with type 2 diabetes mellitus on metformin [abstract 5]. In: Programs and abstracts of the 49th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, Spain. September 23\u201327, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib48","unstructured":"Home P, Stewart M, Yang F. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes: HARMONY 5 Study [abstract 58-LB]. In: Programs and abstracts of the 73rd Annual Scientific Sessions of the American Diabetes Association. Chicago, Illinois. June 21\u201325, 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib49","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.ejim.2009.05.010","article-title":"Incretin therapies: effects beyond glycemic control","volume":"20","author":"Mudaliar","year":"2009","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2014.08.013_bib50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3949\/ccjm.77a.09167","article-title":"Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?","volume":"77","author":"Olansky","year":"2010","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2014.08.013_bib52","unstructured":"U.S. Food and Drug Administration (FDA). Byetta (exenatide)\u2014renal failure. Available at: http:\/\/www.fda.gov\/safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm188703.htm. Accessed June 1, 2014."},{"issue":"9683","key":"10.1016\/j.mcna.2014.08.013_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2014.08.013_bib54","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide\u2014The FDA\u2019s review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2014.08.013_bib55","unstructured":"US Food and Drug Administration. NDA 22-341 Victoza (liraglutide [rDNA origin] injection) risk evaluation and mitigation strategy (REMS). Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM202063.pdf. Accessed June 1, 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1345\/aph.1Q379","article-title":"Clinical efficacy and safety of once-weekly glucagon-like peptide-I agonists in development for treatment of type 2 diabetes mellitus in adults","volume":"46","author":"Tzefos","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.mcna.2014.08.013_bib57","article-title":"Albiglutide: first global approval","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.mcna.2014.08.013_bib58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.mcna.2014.08.013_bib59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2009.03.003","article-title":"Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin\u2014diabetes control and potential adverse events","volume":"23","author":"Ahren","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.mcna.2014.08.013_bib60","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.mcna.2014.08.013_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","article-title":"Cardiovascular effects of DPP-4 inhibition: beyond GLP-1","volume":"55","author":"Fadini","year":"2011","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.mcna.2014.08.013_bib62","unstructured":"Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib63","unstructured":"Onglyza (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2013."},{"key":"10.1016\/j.mcna.2014.08.013_bib64","unstructured":"Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib65","unstructured":"Nesina (alogliptin) [package insert]. Deerfield, IL: Takeda Pharmaceuticals American, Inc; 2013."},{"issue":"12","key":"10.1016\/j.mcna.2014.08.013_bib66","doi-asserted-by":"crossref","first-page":"26327","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.mcna.2014.08.013_bib67","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mcna.2014.08.013_bib68","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib69","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib70","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.mcna.2014.08.013_bib71","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.mcna.2014.08.013_bib72","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.mcna.2014.08.013_bib73","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib74","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.mcna.2014.08.013_bib75","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.mcna.2014.08.013_bib76","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.mcna.2014.08.013_bib77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","article-title":"Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study","volume":"63","author":"Nauck","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib78","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1463-1326.2012.01620.x","article-title":"Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.mcna.2014.08.013_bib79","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1463-1326.2011.01460.x","article-title":"Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study","volume":"13","author":"Kaku","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib80","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1185\/03007990903156111","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Pratley","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mcna.2014.08.013_bib81","unstructured":"U.S. Food and Drug Administration. Safety: Sitagliptin (marketed as Januvia and Janumet)\u2014acute pancreatitis. Available at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm183800.htm. Accessed June 1, 2014."},{"issue":"4","key":"10.1016\/j.mcna.2014.08.013_bib82","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mcna.2014.08.013_bib83","unstructured":"U.S. Food and Drug Administration. Controlled phase 2b\/3 pooled population\u2014day 120 update: stratified analyses of FDA-defined MACE. Available at: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterils\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm149589. Accessed June 1, 2014."},{"issue":"10","key":"10.1016\/j.mcna.2014.08.013_bib84","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers","volume":"48","author":"H\u00fcttner","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.mcna.2014.08.013_bib85","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","article-title":"Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin","volume":"13","author":"Graefe-Mody","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.mcna.2014.08.013_bib86","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.mcna.2014.08.013_bib87","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0002-8703(99)70034-7","article-title":"Therapy of type 2 diabetes, cardiovascular death, and the UGDP","volume":"138","author":"Feinglos","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.mcna.2014.08.013_bib88","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2014.08.013_bib89","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed July 28, 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib90","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2014.08.013_bib91","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9724","key":"10.1016\/j.mcna.2014.08.013_bib92","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2014.08.013_bib93","unstructured":"ClinicalTrials.gov. Available at: http:\/\/clinicaltrials.gov. Accessed July 28, 2014."},{"key":"10.1016\/j.mcna.2014.08.013_bib94","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2014.08.013_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP13176.CSUPPL","article-title":"American Association of Clinical Endocrinologists\u2019 comprehensive diabetes management algorithm 2013 consensus statement","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.mcna.2014.08.013_bib96","first-page":"2650","article-title":"Diabetes in older adults: a consensus report","volume":"35","author":"Kirkman","year":"2012","journal-title":"J\u00a0Am Geriatr Soc"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712514001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712514001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T08:20:37Z","timestamp":1538122837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712514001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0025712514001394"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2014.08.013","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-Based Therapies","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2014.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}